ArticleFrontiers in oncology2026
Spectral CT quantitative parameters for predicting complete ablation after radiofrequency ablation in liver tumors: a retrospective study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Radiofrequency ablation (RFA) is a key minimally invasive treatment for liver tumors, but predicting complete ablation remains challenging. Objective: This study aimed to evaluate the correlation between spectral CT quantitative parameters and complete ablation after RFA for liver tumors. Methods: This retrospective study enrolled 109 patients who underwent RFA for liver tumors and completed preoperative spectral CT scans (January 2022-October 2025). Patients were divided into complete ablation (n=81) and incomplete ablation (n=28) groups based on postoperative MRI. Preoperative spectral CT parameters [normalized iodine concentration (NIC), spectral curve slope (λ-HU), effective atomic number (Z-eff)] in arterial and portal venous phases were measured. Clinical factors including tumor size, AFP, and vessel adjacency were collected. Logistic regression and ROC analysis were used to build a predictive model. Results: The arterial phase NIC, λ-HU, and Z-eff in the lesion parenchymal area of the complete ablation group were significantly lower than those in the incomplete ablation group (P<0.05). Additionally, the proportions of patients with preoperative serum alpha-fetoprotein (AFP) >100 ng/mL, tumors adjacent to major intrahepatic vessels, and a maximum tumor diameter >3 cm were significantly lower in the complete ablation group compared to the incomplete ablation group (P<0.05). Logistic regression analysis identified maximum tumor diameter >3 cm (OR = 8.50, 95% CI: 1.38-52.50), preoperative AFP >100 ng/mL (OR = 9.69, 95% CI: 1.34-70.15), tumor adjacency to major intrahepatic vessels (OR = 12.90, 95% CI: 1.34-124.21), arterial phase NIC (OR = 5.66, 95% CI: 1.49-21.57), λ-HU (OR = 4.32, 95% CI: 1.50-12.47), and Z-eff (OR = 5.12, 95% CI: 1.18-22.22) as independent predictive factors. The combined predictive model constructed from these factors achieved an AUC of 0.933 (95% CI: 0.869-0.972) for predicting complete ablation, with a predictive performance superior to that of any single parameter (P<0.001). Conclusion: Spectral CT quantitative parameters, along with tumor size, vessel adjacency, and AFP level, are significantly associated with complete ablation after RFA for liver tumors and can serve as predictive biomarkers for optimizing individualized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.